CN105560268B - A kind of preparation for being used to suppress influenza infection - Google Patents
A kind of preparation for being used to suppress influenza infection Download PDFInfo
- Publication number
- CN105560268B CN105560268B CN201610056822.0A CN201610056822A CN105560268B CN 105560268 B CN105560268 B CN 105560268B CN 201610056822 A CN201610056822 A CN 201610056822A CN 105560268 B CN105560268 B CN 105560268B
- Authority
- CN
- China
- Prior art keywords
- influenza
- virus
- infection
- preparation
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of preparation for being used to suppress influenza infection.The invention provides a kind of application of preparation in following (1) or (2)：(1) product for suppressing influenza infection is prepared；(2) it is used to suppress influenza infection；The preparation is mainly mixed by Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose；The quality proportioning of the Epigallo-catechin gallate (EGCG), the tannic acid and the astragalus polyose is (0.5 1.0)：(0.5‑1.0)：(0.5‑1.5).The cytotoxicity of compound prescription preparation provided by the present invention is not higher than the control sample Ribavirin for having obtained security clearance, safer.Under the concentration of safety, preventive use preparation provided by the present invention can effectively suppress H 1 N 1 influenza A virus infection, have further research and development for the commercial value of influenza virus-infection inhibitor.
Description
Technical field
The invention belongs to biological technical field, is related to a kind of preparation for being used to suppress influenza infection.
Background technology
Influenza (abbreviation influenza) is ARI caused by influenza virus, and a kind of infectiousness it is strong,
The fast disease of spread speed.Its spittle main through the air, interpersonal contact or the contact with contaminated article
Propagate.Typically clinical symptoms are：It is anxious to play high fever, significantly overall pain, weak and slight respiratory symptom.General autumn and winter
It it is its high-incidence season, caused complication and the phenomena of mortality are very serious.The disease is caused by influenza virus, can be divided into first (A),
Second (B), third (C) three type, antigenic variation often occurs for Alphavirus, infectious strong, propagates rapidly, and a wide range of stream easily occurs
OK.H1N1 is also one kind of influenza A virus.This disease has self limiting, but in infant, the elderly and cardiopulmonary be present
The severe complications such as the easy Complicating Pneumonia In Patients of patient of underlying diseases and cause death.
The reality and potentiality of facing mankind viral infectious threatens increasingly serious, the prevention and control of mankind's reply burst infectious disease
The sense multiplication of pressure day, but more and more actual conditions show：When virus is undergone mutation or new virus occurs and cause to infect
During sick epidemic outbreak, original specific protective agents, which are difficult to performance, should control effect, or even have no curative effect, and human cognitive
Horizontal and the scientific research cycle limitation, make to have a new generation's specificity prevention and treatment medicine of significant curative effect to be difficult in the short time again
Interior release, the rapid diffusion of epidemic situation and the calamity in some areas is easily caused to be broken out, not only to the public health service of locality
Cause greatly to destroy, while huge impact also is caused to the politics and economy of society.Therefore, according to the substantially biological of virus
Characteristic is learned, for the general character target spot of virus infection host cell, new virus infection inhibitor is researched and developed, for tackling viral biography
The continuing challenge for epidemic situation of catching an illness is significant.
Plant compound is referred to as " the 7th class nutrient ", is widely present in conventional food, is that one kind has to health
There is the non-nutritive chemical substance of special role.Correlative study finds that Activities of Some Plants compound has the biology for suppressing virus infection
Activity, and it is increasingly becoming one of focus of antiviral study.Preliminary result of study is shown：The biological effect of plant compound
It is mainly manifested in change of its balance of influence and local microenvironment to cell membrane biological characteristic etc., Activities of Some Plants chemical combination
For thing by being directly embedded into cell membrane lipid bilayer structure, the normal functional flow of change cell membrane and potential are poor, and then
Play certain biological effect.
The content of the invention
It is an object of the invention to provide a kind of preparation for suppressing influenza infection and its application.
Application provided by the present invention is specially a kind of application of preparation in following (1) or (2)：
(1) product for suppressing influenza infection is prepared；
(2) it is used to suppress influenza infection；
The preparation is mainly mixed by Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose；It is described
The quality proportioning of Epigallo-catechin gallate (EGCG), the tannic acid and the astragalus polyose is (0.5-1.0)：(0.5-
1.0)：(0.5-1.5).
In one embodiment of the invention, the preparation for being used to suppress virus infection is specifically by epigallocatechin
Gallate (EGCG), tannic acid and astragalus polyose mix；The Epigallo-catechin gallate (EGCG) (EGCG),
The quality proportioning of the tannic acid and the astragalus polyose is 1：1：1.5.
In the present invention, the suppression influenza infection is following (a) or (b)：
(a) flu-prevention virus infection；
(b) when acting on host or host cell simultaneously with influenza virus, the influenza virus is suppressed to the host
Or the infection of the host cell.
More specifically, in an embodiment of the present invention, the preparation has to the inhibitory action of the influenza infection
Body is presented as：Using mammalian cell as influenza infection object, while influenza infection cell or flowing
The preparation is applied before Influenza Virus infection cell, the half-inhibition concentration of the preparation infected by influenza is with suppressing virus infection
Positive control medicine is compared and significantly reduced.The positive control medicine is specially Ribavirin (Ribavirin).
In the present invention, the mammalian cell (or host cell described in (b)) is specially MDCK (MDCK
Cell).
In the present invention, the influenza virus is influenza A virus.More specifically, the influenza A virus is
H1N1 subtype influenza virus, such as H1N1 subtype influenza virus A/Beijing/501/2009 (H1N1) strain.
The present invention is using H1N1virus as experimental subjects, using the method for observation cytopathy, in different senses
Under the conditions of dye, Epigallo-catechin gallate (EGCG) (EGCG), tannic acid and astragalus polyose these three plants are analyzed respectively
Compound monomer and its mix preparation suppress the rule and feature of influenza infection.As a result confirm：Provided by the present invention three
The cytotoxicity of kind plant compound monomer and compound prescription mixture is not higher than the control sample for having obtained security clearance
Ribavirin, it is safer.Under the concentration of safety, the plant compound such as preventive use EGCG and tannic acid monomer with
And plant extracts compound prescription mixture, it can effectively suppress the infection of H1N1virus.It is provided by the present invention
Preparation have further research and development for influenza virus-infection inhibitor commercial value.
Embodiment
Experimental method used in following embodiments is conventional method unless otherwise specified.
Material used, reagent etc., unless otherwise specified, are commercially obtained in following embodiments.
The quantitative experimental data being related in following embodiments is represented with mean ± standard deviation (± s), is united using SPSS 17.0
Meter software carries out statistical disposition with the method for single factor test level variance analysis comparing data group.
Cell line：MDCK (mdck cell) is ATCC products, and numbering is ATCC CCL-34.Cell is according to a conventional method
Secondary Culture.
Virus：H1N1virus (A/Beijing/501/2009 (H1N1) strain), is recorded in " Xiaoping
Kang,Tao Jiang,Yongqiang Li,Fang Lin,Hong Liu,Guohui Chang,Qingyu Zhu,Ede
Qin,Chengfeng Qin and Yinhui Yang.A duplex real-time RT-PCR assay for
detecting H5N1 avian influenza virus and pandemic H1N1influenza
virus.Virology Journal,2010,7:113 " one texts, the public can obtain at applicant, be only used for repeating the present invention
Experiment uses.
Nutrient solution：1), cell growth nutrient solution：With DMEM culture mediums (Glibo Products) for mother liquor, it is separately added into
10% (volume fraction) hyclone (Sigma Products), 0.2mg/ml glutamine (Glibo Products), 100U/ml
Penicillin, streptomysin.2), cell maintenance culture solution, hyclone content are 2% (volume fraction), remaining and 1) all same.
3), virus multiplication nutrient solution：Add 2 μ g/ml TPCK-Trypsin (Sigma Products), remaining composition and 1) in cell
Grown cultures liquid phase is same.
Epigallo-catechin gallate (EGCG) (EGCG)：Sigma Products (purity assays>95%), production code member
For E4143, CAS#989-51-5.
Tannic acid (Tannin)：Sigma Products (purity assays>99%), production code member V900190；CAS#
1401-55-4。
Astragalus polyose (APS)：Shanghai Jin Sui bio tech ltd product (2- (Chloromethyl) -4- (4-
Nitrophenyl) -1,3-thiazole) (purity assay>70%), production code member JS11328；CAS#89250-26-0.
Positive control medicine：Ribavirin (Ribavirin), Mei Lun biotech firms product.Because not having by changing also at present
Become the standard positive control medicine that host cell membrane property suppresses virus infection.This research is with the most frequently used medicine profit antiviral at present
Ba Weilin is as control.Dissolved before experiment with PBS, 2560 μ g/ml filterings are made, after degerming, -20 DEG C of preservations.
Inverted phase contrast microscope：Japanese Olympus Products.
Cell culture incubator：U.S.'s Thermo Products.
Multifunctional enzyme instrument：Molecular Devices companies of U.S. SpectraMax M5 type multi-function microplate readers.
1st, cell recovery and passage
Mdck cell is taken out in liquid nitrogen respectively, 37 DEG C of water-baths, after thawing, 5min is centrifuged with 1000rpm, abandons supernatant, is added
Appropriate cell growth nutrient solution, piping and druming is uniform repeatedly, and it is about 2 × 10 to make cell density5Individual/ml is thin in T25 with 10ml/ bottles
In born of the same parents' blake bottle, cellar culture in cell culture incubator.24h is after Microscopic observation, the adherent situation of cell, after 48-72h, or treats
Cell growth to density be about 95% when, abandon original fluid, add PBS, rinsing twice, 0.5ml 0.25%
(0.25g/100ml) EDTA, digestion is incubated in 37 DEG C of incubators, when cellular contraction change bowlder, be rapidly added cell growth training
Nutrient solution, terminate digestion, repeatedly after piping and druming uniformly, centrifuged with 1000rpm, 5min, abandon supernatant, make suspension cell concentration be about 1 ×
105Individual/ml, every bottle of 10ml/, T25 Tissue Culture Flasks are moved into, place cell culture incubator, carry out routine passage culture.
2nd, virus multiplication
The T25 Tissue Culture Flasks that cell density is about 80% are taken, abandon stoste, with PBS, are rinsed twice, to remove blood
Clear residual, addition have diluted viral (dilution is PBS), inoculum concentration MOI=0.01, and 1ml culture mediums, and rolling is even,
It is placed in cell culture incubator and adsorbs 1h, abandon supernatant, every bottle adds the corresponding virus multiplication nutrient solutions of 10ml.Observe cytopathy, 48-
After 72h, or when cytopathy is up to more than 75%, poison is received, supernatant is taken, multigelation 3 times, with 3000rpm, 4 DEG C, centrifuges
5min, supernatant is dispensed, and determine virus titer TCID50。
3rd, virus titer TCID50Measure
Determined, with single cell suspension, added in 96 hole microtest plates, per the μ of hole 200 using cytopathogenic effect method (CPE)
L, cell concentration is set to reach 2 × 105Individual/ml, 48-72h is cultivated in cell culture incubator, until when cell monolayer density is about 80%,
Take out, abandon culture medium, twice (MDCK is rinsed with the maintenance culture medium containing 2 μ g/ml TPCK-Trypsin) is rinsed with PBS, utilizes disease
10 times of gradient dilutions of virus stock solution used are 10 by malicious Multiplying culture liquid-3~10-13, arranged per the hole one of concentration gradient 8, per the μ l of hole 100, if
Vertical blank control two is arranged, and 1h is adsorbed in cell culture incubator, abandons supernatant, and rear add maintains the μ l of nutrient solution 200.Seen under per solar eyepiece
Examine, when virus control group cytopathy to record experimental result when " ++++".Calculated by Reed-Muench Liang Shi methods, virus drop
Spend TCID50.Every group of strain, in triplicate.
lgTCID50=(percentage -50% for being higher than 50% lesion rate)/(percentage for being higher than 50% lesion rate-it is less than
The percentage of 50% lesion rate) difference+lg (dilution factor for being higher than 50% lesion rate) between × dilution factor logarithm.
The preparation of embodiment 1, plant extracts compound prescription inhibitors of viral infection
By Epigallo-catechin gallate (EGCG) (EGCG), tannic acid and astragalus polyose according to quality proportioning be 1：1：
1.5 ratio is well mixed, and obtains plant extracts compound prescription preparation.
Dissolved before experiment with PBS, 2560 μ g/ml (EGCG, tannic acid and astragalus polyose in the solution total is made
Concentration) filtering, after degerming, -20 DEG C save backup.
Embodiment 2, cell toxicity test
The compound prescription preparation that the present embodiment is prepared using dimethyl diaminophenazine chloride phagocytosis method measure embodiment 1 is to mammalian cell
Cytotoxicity.Concrete operations are as follows：
Compound prescription formulation soln (2560 μ g/ml) multiple proportions gradient dilution prepared by embodiment 1, obtains 20 μ g/ml, and 40
μ g/ml, 80 μ g/ml, 160 μ g/ml, 320 μ g/ml, 640 μ g/ml, 1280 μ g/ml totally 6 concentration.Then by different dilution factors
Dilution be added separately to culture and have in 96 porocyte culture plates that mdck cell and cell density are about 80%, per the μ of hole 100
L, each dilution factor do 4 multiple holes, using normal cell (being not added with compound prescription preparation) as control, after acting on 2h, abandon
By test solution, cell maintenance culture solution is added, 200 μ l are added per hole, is placed in cell culture incubator and cultivates, after 48h, is added per hole
The μ l of 0.1% (0.1g/100mL) dimethyl diaminophenazine chloride 25, after acting on 1.5h in 37 DEG C, the liquid in every hole is suctioned out, and 2 are rinsed with PBS
It is secondary.100 μ l cell pyrolysis liquid (acetic acid is added per hole:Ethanol:Water=1:50:49, volume ratio), 100 μ l are added per hole, and set
Blank control, using SpectraMax M5 multi-function microplate readers (Molecular Devices companies of the U.S.), setting absorbs light
Wavelength is 492nm, determines OD values, and by one-way analysis of variance, more each concentration group (normal cell, i.e., does not add with control group
Add compound prescription preparation) significant difference between OD values, determine the maximal non-toxic of compound prescription preparation prepared by embodiment 1
Concentration (i.e. the Cmax of no difference of science of statistics compared with control group OD values).
Experiment sets Epigallo-catechin gallate (EGCG) (EGCG), tannic acid and astragalus polyose these three chemical combination simultaneously
The monomer of thing compares as the monomer of compound prescription preparation；And viral infection resisting positive control drug Ribavirin is set as positive
Control.
It is as a result as shown in table 1, it is seen that：Compound prescription preparation is 1280 μ g/ml to the maximal non-toxic concentration of mdck cell,
Better than the maximal non-toxic concentration (640 μ g/ml) of marketed drug Ribavirin.It can be seen that plant compound prepared by embodiment 1 is answered
Close pharmaceutical formulation and keep preferable security.
The cell maximal non-toxic experimental result of the plant compound monomer of table 1 and compound prescription preparation
Embodiment 3, influenza infection suppress experiment
The suppression effect for the compound prescription preparation infected by influenza infection that the present embodiment is prepared using CPE methods measure embodiment 1
Fruit.It is H1N1virus A/Beijing/501/2009 (H1N1) strain for examination influenza virus.
Take that to have grown up to Monolayer growth of cells density be about that 80% culture there are 96 well culture plates of mdck cell, outwell culture
Liquid, after rinsing cell 3 times with PBS, respectively with A, compound prescription preparation prepared by embodiment 1 is added under the conditions of tri- kinds of B, C：
A. in viruses adsorption simultaneously：By 2 isometric × 100TCID50H1N1virus virus liquid and 2 times
After the tested material solution mixing of concentration, the μ l/ holes of mixed liquor 100 are added in Tissue Culture Plate, in cell culture incubator, treat virus
After adsorbing 1h, it is abandoned.Behind PBS flushing cells face 3 times, cell maintenance culture solution is added.
B. before viruses adsorption：The μ l of tested material solution 100 of corresponding dilution factor are added per hole, abandon tested material solution, PBS punchings
After washing cell face 3 times, addition titre is 100TCID50H1N1virus the μ l of virus liquid 100, in cell culture incubator
In, abandon it after viruses adsorption 1h.Behind PBS flushing cells face 3 times, cell maintenance culture solution is added.
C. after viruses adsorption：100TCID50H1N1virus the μ l/ holes of virus liquid 100, in cell culture
In case, it is abandoned after viruses adsorption 1h.The tested material solution of corresponding dilution factor is added per the μ l of hole 100, tested material solution is abandoned, in thin
Virus liquid is abandoned after adsorbing 1h in born of the same parents' incubator.After PBS is rinsed 3 times, cell maintenance culture solution is added.
Wherein, tested material is these three changes of Epigallo-catechin gallate (EGCG) (EGCG), tannic acid and astragalus polyose
Compound prescription preparation prepared by the monomer of compound, embodiment 1, or viral infection resisting positive control drug Ribavirin.Tested material is molten
The concentration of liquid sets following concentration gradient：20 μ g/ml, 40 μ g/ml, 80 μ g/ml, 160 μ g/ml, 320 μ g/ml, 640 μ g/ml,
1280μg/ml。
(positive control is only addition 100TCID with positive controls for every group of Setup Experiments blank control50Virus, blank pair
According to only adding cell maintenance culture solution), cultivated in cell culture incubator, observed daily under inverted microscope, work as virus control
Group (i.e. positive controls) cytopathy is records experimental result when " ++++".Half suppression is calculated by Reed-Muench Liang Shi methods
Concentration IC processed50。
As a result show：Plant extracts compound prescription preparation and profit prepared by EGCG, tannic acid, astragalus polyose, embodiment 1
(A represents viruses adsorption while adds inhibitor group Ba Weilin, and B adds inhibitor before representing viruses adsorption in a manner of three kinds respectively
Group, C add inhibitor group after representing viruses adsorption) when intervening H 1 N 1 influenza A virus infection, tannic acid is under the conditions of C and yellow
Astragalus polysaccharides can not effectively suppress outside virus infection under three conditions, EGCG, plant extracts compound prescription preparation and Li Ba
Wei Lin can suppress viral infection under three conditions.Wherein, compound prescription preparation is administered simultaneously effect with infection before infection
Optimal, half-inhibition concentration is only that the half-inhibition concentration of 92 μ g/ml, EGCG, tannic acid and Ribavirin is substantially high before absorption
In compound prescription preparation.But in the case of being administered after infection, Ribavirin obviously has greater advantages.In monomer inhibitor
In, tannic acid adds while viruses adsorption, and it suppresses, and the infectious effect of virus is best, and viral half-inhibition concentration is 234
±36μg/ml.Concrete outcome is shown in Table 2.
2 each inhibitor of table infects half-inhibition concentration (IC to A (H 1 N 1) virus50)
Note：* represent compared with Ribavirin group, p<0.05.
The experimental result of integrated embodiment 2 and 3, it is seen that：The cytotoxicity of compound prescription preparation provided by the present invention is not
It is safer higher than the control sample Ribavirin for having obtained security clearance.Under the concentration of safety, preventive use
Plant extracts compound prescription preparation provided by the present invention, it can effectively suppress the infection of H1N1virus.This
The there is provided compound prescription preparation of invention has further research and development for the commercial value of influenza virus-infection inhibitor.
The inhibition that comparative example, the plant extracts compound prescription preparation infected by influenza of different ratio infect compares
For experimental method referring to embodiment 3, tested material is the compound prescription preparation of the preparation of embodiment 1, control compound prescription system
Agent 1, control compound prescription preparation 2, control compound prescription preparation 3, or viral infection resisting positive control drug Ribavirin, remaining behaviour
Make with embodiment 3.Wherein, matching somebody with somebody for compound prescription preparation 1, control compound prescription preparation 2 and control compound prescription preparation 3 is compareed
Side is as follows：
Compare compound prescription preparation 1：By Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose according to quality
Match as 0.5：1：0.5 ratio mixes.
Compare compound prescription preparation 2：By Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose according to quality
Match as 1：0.5：1 ratio mixes.
Compare compound prescription preparation 3：By Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose according to quality
Match as 1：1：1 ratio mixes.
As a result show：Compound prescription preparation 1, control compound prescription preparation 2 and control compound prescription preparation 3 are compareed to A type
Half-inhibition concentration (the IC of H1N1 influenza infections50) it is substantially less than prepared by embodiment 1 under the conditions of tri- kinds of A, B and C
Compound prescription preparation (p<0.05).Concrete outcome is referring to table 3.
The different composite pharmaceutical formulation of table 3 is to H 1 N 1 influenza A virus infection half-inhibition concentration (IC50)
Note：* represent compared with Ribavirin group, p<0.05.# expressions are compared with the compound prescription preparation group of embodiment 1, p<
0.05。
Claims (3)
1. a kind of preparation is preparing the application in being used to suppress the product of influenza infection；
The preparation is mixed by Epigallo-catechin gallate (EGCG), tannic acid and astragalus polyose；The epi-nutgall
The quality proportioning of catechin and gallate, the tannic acid and the astragalus polyose is 1：1：1.5；
The suppression influenza infection is as follows（a）Or（b）：
（a）Flu-prevention virus infection；
（b）When acting on host or host cell simultaneously with influenza virus, suppress the influenza virus to the host or institute
State the infection of host cell.
2. application according to claim 1, it is characterised in that：The influenza virus is influenza A virus.
3. application according to claim 2, it is characterised in that：The influenza A virus is H1N1 subtype influenza virus.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610056822.0A CN105560268B (en) | 2016-01-27 | 2016-01-27 | A kind of preparation for being used to suppress influenza infection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610056822.0A CN105560268B (en) | 2016-01-27 | 2016-01-27 | A kind of preparation for being used to suppress influenza infection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105560268A CN105560268A (en) | 2016-05-11 |
| CN105560268B true CN105560268B (en) | 2018-03-23 |
Family
ID=55871287
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610056822.0A Expired - Fee Related CN105560268B (en) | 2016-01-27 | 2016-01-27 | A kind of preparation for being used to suppress influenza infection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105560268B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017124831A1 (en) * | 2016-01-18 | 2017-07-27 | 中国人民解放军疾病预防控制所 | Broad-spectrum viral infection inhibitor |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101744807A (en) * | 2009-12-22 | 2010-06-23 | 江苏天晟药业有限公司 | Epigallocatechin-3-gallate pharmaceutical composition and freeze-dried powder injection thereof |
| JP2011084549A (en) * | 2009-10-16 | 2011-04-28 | Woongjin Coway Co Ltd | Composition containing tannic acid and used for preventing infection of influenza virus, air filter containing the composition, and air cleaner containing the filter |
| CN102037978A (en) * | 2009-10-16 | 2011-05-04 | 熊津豪威株式会社 | Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter |
| CN104083427A (en) * | 2014-07-30 | 2014-10-08 | 河南中医学院 | Compound astragalus polysaccharide particle for preventing and treating avian influenza |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110052727A1 (en) * | 2009-08-31 | 2011-03-03 | Hanan Polansky | Anti Influenza Nutritional Supplements |
-
2016
- 2016-01-27 CN CN201610056822.0A patent/CN105560268B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011084549A (en) * | 2009-10-16 | 2011-04-28 | Woongjin Coway Co Ltd | Composition containing tannic acid and used for preventing infection of influenza virus, air filter containing the composition, and air cleaner containing the filter |
| CN102037978A (en) * | 2009-10-16 | 2011-05-04 | 熊津豪威株式会社 | Composition for prevention of influenza viral infection comprising tannic acid, air filter comprising the same and air cleaning device comprising the filter |
| CN101744807A (en) * | 2009-12-22 | 2010-06-23 | 江苏天晟药业有限公司 | Epigallocatechin-3-gallate pharmaceutical composition and freeze-dried powder injection thereof |
| CN104083427A (en) * | 2014-07-30 | 2014-10-08 | 河南中医学院 | Compound astragalus polysaccharide particle for preventing and treating avian influenza |
Non-Patent Citations (1)
| Title |
|---|
| 黄芪多糖抗流感病毒的实验研究;李丽娅 等;《中国中医药科技》;20021231;第9卷(第6期);摘要 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105560268A (en) | 2016-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105687226B (en) | A kind of preparation for being used to suppress coronavirus infection | |
| Ahidjo et al. | Current perspective of antiviral strategies against COVID-19 | |
| CN105535012B (en) | A kind of broad spectrum activity inhibitors of viral infection | |
| Ward et al. | Oseltamivir (Tamiflu®) and its potential for use in the event of an influenza pandemic | |
| Klawikkan et al. | Effect of Thai medicinal plant extracts against Dengue virus in vitro | |
| CN107441094B (en) | Nilotinib as medicine for treating dengue virus infection and pharmaceutical application thereof | |
| Liu et al. | Characterization of poliovirus variants selected for resistance to the antiviral compound V-073 | |
| CN105497058B (en) | A kind of preparation for being used to suppress enterovirus infection | |
| CN105560268B (en) | A kind of preparation for being used to suppress influenza infection | |
| CN105560351B (en) | It is a kind of for inhibiting the preparation of adenovirus infection | |
| CN105663218B (en) | It is a kind of for inhibiting the preparation of poxvirus infection | |
| CN106983736B (en) | Drug and its pharmaceutical applications of the Tatanan A as treatment dengue virus infection | |
| CN102274234A (en) | Application of ganoderic acid Y to preparation of medicament for treating or preventing enterovirus 71 infection | |
| WO2017124831A1 (en) | Broad-spectrum viral infection inhibitor | |
| TWI359669B (en) | ||
| CN108042537A (en) | Aromatic ester compound is used to prepare anti-EV71 viral inhibitors | |
| CN104203265A (en) | Antiviral composition against flavivirus | |
| CN104095842A (en) | Application of EGCG palmitate in preparing medicines for treating or preventing human enterovirus 71 infection | |
| Hammarlund et al. | Traditional smallpox vaccination with reduced risk of inadvertent contact spread by administration of povidone iodine ointment | |
| Wei et al. | Antiviral effects and mechanisms against EV71 of the novel 2-benzoxyl-phenylpyridine derivatives | |
| CN115869324B (en) | Application of Efavirennz in preparation of anti-enterovirus drugs | |
| CN112057453B (en) | Use of ENC002 and its analogues for treating or preventing enterovirus infection | |
| CN107823215A (en) | Application of the scutelloside in the medicine for preparing preventing and treating zika virus infection | |
| CN105030797B (en) | The composition of a kind of anti-japanese encephalitis virus infection and its application | |
| Mendoza | Chloroquine and Hydroxychloroquine for the Treatment of COVID-19 patients: What Every Clinician Should Know |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180323 Termination date: 20220127 |